Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma 111Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Lymphoma, Non-Hodgkin 105Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Large B-Cell, Diffuse 84Lymphoma, Follicular 68Hodgkin Disease 54Burkitt Lymphoma 52Multiple Myeloma 51Lymphoma, B-Cell 51Recurrence 46Lymphoma, Mantle-Cell 46Leukemia, Myeloid, Acute 44Leukemia 37Neoplasms 35Hematologic Neoplasms 32Myelodysplastic Syndromes 29Lymphoma, B-Cell, Marginal Zone 26Waldenstrom Macroglobulinemia 22Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, T-Cell 18Lymphoma, T-Cell, Peripheral 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Leukemia, B-Cell 16Lymphoma, Large-Cell, Anaplastic 15Sarcoma 13Leukemia, Biphenotypic, Acute 13Mycosis Fungoides 11Melanoma 10Lymphoma, T-Cell, Cutaneous 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × Lymphoid × 30 days × Clear all
NCT06915766 2026-05-28

Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

Cogent Biosciences, Inc.

Available
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT05362773 2026-05-22

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

MacroGenics

Phase 1 Recruiting
130 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Hairy Cell, Myelodysplastic Syndromes, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡